New data on belatacept, an investigational selective T cell costimulation blocker being studied for use in renal transplantation by Bristol-Myers Squibb Company (NYSE:BMY), will be presented at the American Transplant Congress April 30 - May 4, 2011 in Philadelphia. In total, 21 abstracts from company-sponsored studies will be presented during the congress, including seven oral presentations related to kidney transplantation. The data being presented highlights the broad clinical program for belatacept, a key compound supporting Bristol-Myers Squibb's strategy to discover and develop targeted therapies for serious diseases.
Key data being presented include:
- Three-Year Outcomes from BENEFIT: A Phase III Study of Belatacept vs. Cyclosporine in Kidney Transplant Recipients
- 3-Year Safety Profile of Belatacept in Kidney Transplant Recipients from the BENEFIT and BENEFIT-EXT Studies
- Renal Function at 2 Years in Kidney Transplant Recipients Switched from Cyclosporine or Tacrolimus to Belatacept: Results from the Long-Term Extension of a Phase II Study
- Three year Outcomes by Donor Type in Phase III Studies of Belatacept vs. Cyclosporine in Kidney Transplantation (BENEFIT & BENEFIT-EXT)
"Transplant patients often face multiple medical challenges following surgery" said Brian Daniels, M.D., senior vice president, Global Development and Medical Affairs, Bristol-Myers Squibb. "The breadth of Bristol-Myers Squibb's clinical data on belatacept at the American Transplant Congress demonstrates our ongoing commitment to address the unmet medical needs of patients in the renal transplant community."
GLP-1 receptor agonists reduce kidney failure risk and cardiovascular events